Tinlarebant
- Generic Name
- Tinlarebant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21F5N4O2
- CAS Number
- 1821327-95-0
- Unique Ingredient Identifier
- 63WI9S8P1M
- Associated Conditions
- -
- Associated Therapies
- -
Belite Bio Announces Presentations at the American Academy
Belite Bio to present Tinlarebant Phase II data for Stargardt disease at AAO 2024, highlighting its potential to reduce vitamin A-based toxins in retinal diseases.
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial
Belite Bio has initiated the Phase 2/3 DRAGON II trial at Tokyo Medical Center, evaluating Tinlarebant for STGD1. The trial aims to assess efficacy, safety, and tolerability in 60 adolescent subjects across the US, UK, and Japan. Tinlarebant is an oral therapy targeting vitamin A-based retinal toxins.
Belite Bio doses the first patient at the Tokyo Medical Center in the Phase 2/3 DRAGON II clinical trial
Belite Bio has dosed the first patient in the Phase 2/3 DRAGON II trial evaluating Tinlarebant for STGD1 at Tokyo Medical Center. The trial aims to assess Tinlarebant's efficacy, safety, and tolerability in 60 adolescent STGD1 subjects across the US, UK, and Japan. Tinlarebant is an oral therapy designed to reduce vitamin A-based retinal toxins.
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant
Phase 2/3 DRAGON II trial to evaluate Tinlarebant's efficacy, safety, and tolerability in 60 adolescent STGD1 subjects across U.S., U.K., and Japan. Phase 1b completed in Japan. Tinlarebant granted Orphan Drug and Sakigake Designation in Japan. Pivotal global Phase 3 trial (PHOENIX) ongoing with over 200 GA subjects enrolled.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath